302 related articles for article (PubMed ID: 17409993)
1. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
Noble J; Ellis PM; Mackay JA; Evans WK;
J Thorac Oncol; 2006 Nov; 1(9):1042-58. PubMed ID: 17409993
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Ardizzoni A; Tiseo M
J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
[TBL] [Abstract][Full Text] [Related]
4. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Rigas JR
Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
[TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
[TBL] [Abstract][Full Text] [Related]
6. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
7. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.
Nelli F; Naso G; De Pasquale Ceratti A; Saltarelli R; Dauria G; Lugini A; Ferraldeschi R; Picone V; Moscetti L; Cortesi E
J Chemother; 2004 Aug; 16(4):392-9. PubMed ID: 15332716
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Trisolini R; Toschi L; Bartolini S; Metro G; Crinò L
Oncology (Williston Park); 2005 Jul; 19(8):989-95; discussion 995-6, 999, 1003-4, passim. PubMed ID: 16131043
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer.
Lilenbaum R; Rubin M; Samuel J; Boros L; Chidiac T; Seigel L; Dowlati A; Graham P; Beaumont J; Du H
J Thorac Oncol; 2007 Apr; 2(4):306-11. PubMed ID: 17409802
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy in patients with advanced non-small cell lung cancer.
Bedano PM; Hanna NH
J Thorac Oncol; 2006 Jul; 1(6):582-7. PubMed ID: 17409922
[TBL] [Abstract][Full Text] [Related]
11. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Ganguli A; Wiegand P; Gao X; Carter JA; Botteman MF; Ray S
Qual Life Res; 2013 Jun; 22(5):1015-26. PubMed ID: 22806607
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
14. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK;
J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
16. [Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)].
Manegold C
Onkologie; 2003 Dec; 26 Suppl 7():26-32. PubMed ID: 14716139
[TBL] [Abstract][Full Text] [Related]
17. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
18. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
[TBL] [Abstract][Full Text] [Related]
20. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
